Physician profile
Christopher Gentile
NPI 1235118134
$2,612.82
in general payments reported to CMS, 2019-2025
17 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $98.29 · 2021: $546 · 2022: $629 · 2023: $567 · 2024: $363 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Entertainment: $44.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.62 |
| Entertainment | $44.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $878.15 | 2022-2025 | Infuse, Miebo, Btod |
| Alcon Vision LLC | $622.76 | 2019-2025 | Precision7, Total30 |
| Oyster Point Pharma, INC. | $148.49 | 2022-2024 | Ryzumvi |
| Allergan, INC. | $142.40 | 2021 | |
| Coopervision INC. | $130.62 | 2019-2021 | |
| Glaukos Corporation | $126.21 | 2023 | |
| Rxsight INC | $124.43 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.13 | 2019-2021 | |
| Sight Sciences, INC. | $73.32 | 2022-2023 | Tearcare System |
| Visioneering Technologies, INC. | $55.63 | 2019 | |
| Depuy Synthes Sales INC. | $53.63 | 2021 | |
| Sun Pharmaceutical Industries INC. | $46.75 | 2023-2025 | Cequa |
| Optos, INC. | $44.18 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $36.48 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $24.92 | 2024 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.61 | 2022 | |
| Lkc Technologies, INC. | $11.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gentile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.